Physician profile
Richard Brian Gaynor
NPI 1033451083
$3,697,421.94
in general payments reported to CMS, 2019-2025
2 companies · $494K in 2025
The $494K reported for 2025 was more than what 99% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $800K · 2020: $500K · 2021: $464K · 2022: $477K · 2023: $472K · 2024: $490K · 2025: $494K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1.4M · Travel and Lodging: $38K · Food and Beverage: $4,642.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,413,967.21 |
| Travel and Lodging | $38,058.75 |
| Food and Beverage | $4,641.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $3,697,407.73 | 2019-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.21 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Gaynor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.